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Abstract 
Context: Over the last decade, vitamin D has emerged as a risk determinant for type 2 diabetes and 
vitamin D supplementation has been hypothesized as a potential intervention to lower diabetes risk. 
Recently, several trials have reported on the effect of vitamin D supplementation on diabetes prevention 
in people with prediabetes.
Evidence Acquisition: A comprehensive literature review was performed using PubMed, Embase, and 
ClinicalTrials.gov to identify: (1) recent meta-analyses of longitudinal observational studies that report 
on the association between blood 25-hydroxyvitamin D (25[OH]D) level and incident diabetes, and (2) 
clinical trials of adults with prediabetes that have reported on the effect of vitamin D supplementation 
on incident diabetes.
Evidence Synthesis: Longitudinal observational studies report highly consistent associations between 
higher blood 25(OH)D levels and a lower risk of incident diabetes in diverse populations, including 
populations with prediabetes. Trials in persons with prediabetes show risk reduction in incident diabetes 
with vitamin D supplementation. In the 3 large trials that were specifically designed and conducted for 
the prevention of diabetes, vitamin D supplementation, when compared with placebo, reduced the risk 
of developing diabetes by 10% to 13% in persons with prediabetes not selected for vitamin D deficiency.
Conclusions: Results from recent trials are congruent with a large body of evidence from observational 
studies indicating that vitamin D has a role in modulating diabetes risk. Participant-level meta-analysis 
of the 3 largest trials should provide a more refined estimate of risk reduction and identify patient 
populations that are likely to benefit the most from vitamin D supplementation.
Freeform/Key Words: vitamin D, diabetes, prediabetes, type 2 diabetes, prevention
Diabetes is one of the fastest growing health challenges of the 
21st century, as the number of adults living with diabetes has 
more than tripled over the past 20 years. It is estimated that 
9.3% of adults aged 20–79 years worldwide (approximately 
463 million) and 12% of US adults aged older than 18 years 
(approximately 30 million) are living with diabetes (1). 
More than 9/10 people with diabetes have type 2 diabetes. 
An estimated one-third of the adult US population (approxi-
mately 84 million) is at risk for type 2 diabetes (ie, have 
prediabetes), based on having a fasting glucose (FG) or hemo-
globin A1c (HbA1c) level above the normal range but below 
the threshold for diabetes (2, 3). People with prediabetes pro-
gress to diabetes at a rate of about 5% to 10% per year (4). 
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obese and who have an impaired glucose tolerance and ele-
vated FG levels can slow the progression to diabetes with in-
tensive lifestyle changes that lead to weight loss (5). However, 
sustaining lifestyle changes long-term is challenging, and 
there is always residual risk even after successful weight loss 
and maintenance. Therefore, simple, inexpensive, and sus-
tainable approaches that can be applied at the public health 
level to complement lifestyle changes are needed to lower the 
risk of type 2 diabetes in persons with prediabetes.
Over the last decade, low blood 25-hydroxyvitamin 
D (25[OH]D) level has emerged as a risk factor for type 
2 diabetes, and vitamin D supplementation has been hy-
pothesized as a potential intervention to lower diabetes 
risk (6, 7). Observational studies strongly support an in-
verse association between blood 25(OH)D level and risk 
of developing type 2 diabetes in diverse cohorts of vari-
able diabetes risk, especially in persons with prediabetes 
(8, 9). Results from short-term mechanistic studies offer a 
biologic plausibility to the hypothesis (10, 11). Recently, 
several trials testing the effect of vitamin D supplementa-
tion to reduce the rate of progression to diabetes in people 
with prediabetes have been completed (12–19).
We sought to evaluate and synthesize the available evi-
dence to determine the role of vitamin D in the prevention 
of type 2 diabetes.
Review Strategy and Literature Search
Although results from high-quality randomized controlled 
trials are typically considered to be the highest level of evi-
dence to establish whether an intervention has an effect 
on the outcome of interest, the totality of evidence from 
different lines of research should be considered when 
establishing causality. In synthesizing the available evi-
dence, we have used the Bradford Hill general guidelines 
for causality and have structured our review to address 
these guidelines in relation to vitamin D and the prevention 
of type 2 diabetes (Table 1) (20).
A comprehensive literature review was performed using 
PubMed, Embase, and ClinicalTrials.gov to identify: (1) 
recent meta-analyses of longitudinal observational studies 
that report on the association between blood 25(OH)D 
level and incident diabetes, and (2) clinical trials of adults 
with prediabetes that have reported on the effect of vitamin 
D supplementation on incident diabetes.
Overview of vitamin D physiology and plausible 
mechanistic links to the pathophysiology of type 
2 diabetes
Vitamin D, obtained either from oral sources or cutaneous 
biosynthesis upon sun exposure, is hydroxylated first in 
the liver to 25(OH)D, and then in the kidneys to become 
the active form 1,25-dihydroxyvitamin D (1,25[OH]2D). 
These vitamin D metabolites are transported in the circu-
lation bound primarily to vitamin D binding protein and 
only a small fraction circulates in the free form. The free 
1,25(OH)2D form binds to the nuclear vitamin D receptor 
(VDR), which regulates hundreds of genes (21). Circulating 
25(OH)D has a long half-life, can be readily measured, and 
correlates well with known vitamin D effects; therefore, 
it is used in clinical and research settings as a marker of 
vitamin D status.
The main effect of vitamin D is to increase the intes-
tinal absorption of calcium. Severe vitamin D deficiency 
leads to rickets in children and osteomalacia in adults. 
However, due to the wide tissue distribution of the VDR 
and extrarenal activation of 25(OH)D to 1,25(OH)2D, it 
is believed that vitamin D has extraskeletal effects (22). 
Accordingly, low blood 25(OH)D levels have been as-
sociated with numerous diseases, including the risk of 
developing type 2 diabetes (23).
The hypothesis that vitamin D status may influence the 
risk of type 2 diabetes is biologically plausible, because 
both impaired pancreatic beta-cell function and insulin 
resistance have been reported with low blood 25(OH)D 
levels (10). Importantly, critical tissues in the physiology of 
glucose homeostasis, such as the beta cell, express 1-alpha-
hydroxylase (CYP27B1) and can convert inactive vitamin 
D to its active metabolite (24). Furthermore, vitamin D de-
ficiency in mice leads to reduced insulin secretion that can 
be restored by vitamin D supplementation (25). Systemic 
inflammation is another component in the pathophysi-
ology of type 2 diabetes, and low blood 25(OH)D levels 
have been associated with high levels of inflammatory 
markers (26).
In humans, mechanistic studies show inconsistent re-
sults. Vitamin D supplementation for participants at 
high risk for or with newly diagnosed type 2 diabetes 
has shown an effect (27) as well as no effect (28) on in-
sulin sensitivity and secretion. However, such studies are 
inconclusive because they are underpowered; have in-
cluded populations with sufficient vitamin D status, with 
Table 1. Prerequisites for Effect (Causal Association) of 
Vitamin D for Prevention of Type 2 Diabetes.
• Plausible mechanism(s)
• Temporal relationship
• Strength of the association
• Dose response
•  Consideration of alternative explanations
• Experimental evidence (ie, clinical trials)
• Challenges of vitamin D clinical trials
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a low risk for diabetes or with established diabetes; have 
co-administered vitamin D with other interventions, which 
may confound the effect of vitamin D; or have followed 
participants for short periods of time (about 2–6 months), 
which are likely inadequate to affect the pathophysiology 
of type 2 diabetes.
Despite basic research studies providing some support 
for mechanisms in favor of vitamin D having an effect on 
the pathophysiology of type 2 diabetes, one needs to be 
careful of arguments in favor of biologic rationale, as the 
research history is filled with large trials that did not con-
firm a hypothesis that had a strong biological rationale 
from basic research.
Temporal relationship, strength of association, 
and dose response
Evidence to support the prerequisites of the temporal 
relationship, strength of the association, and dose re-
sponse (Table 1) comes from observational studies. Many 
cross-sectional studies have reported inverse associations 
between vitamin D status and glucose intolerance; how-
ever, cross-sectional studies are not informative and can 
only be considered hypothesis-generating, as the direction-
ality of the association cannot be established.
Several observational, longitudinal studies conducted 
in diverse cohorts have reported consistent inverse associ-
ations between blood 25(OH)D levels and the risk of in-
cident diabetes. Results have been summarized in recent 
meta-analyses with similar findings. Song et  al combined 
data from 21 longitudinal cohorts (total of 76 220 partici-
pants; 4996 incident diabetes cases) and estimated a 38% 
risk reduction for incident diabetes in the highest versus 
the lowest category of blood 25(OH)D level (8). The asso-
ciation did not differ by sex, duration of follow-up, cohort 
sample size, 25(OH)D assay method, or diabetes diag-
nostic criteria. Afzal et al combined data from 16 longitu-
dinal cohorts (total of 72 204 participants; 4877 incident 
diabetes cases) and reported that the bottom quartile of 
blood 25(OH)D level was associated with a 50% higher 
risk for incident diabetes compared with the top quartile 
(29). Ye et al included data from 22 longitudinal cohorts 
(89 698 noncases; 8492 diabetes cases) and reported that a 
10-ng/mL lower 25(OH)D level was associated with a 22% 
higher risk of incident diabetes (30).
Notably, in the observational studies, the highest cat-
egory of 25(OH)D level (conferring the lowest risk of dia-
betes) was in the 25 to 30  ng/mL range, and the lowest 
category (conferring the highest risk of diabetes) was in the 
10 to 15 ng/mL range. In the meta-analysis by Song et al, a 
spline regression model showed that higher blood 25(OH)D 
levels were monotonically associated with a lower diabetes 
risk, without an apparent plateau (8). However, few ob-
servational studies have included enough participants with 
25(OH)D levels higher than 30 ng/mL; therefore, it is not 
clear whether achieving and maintaining higher 25(OH)D 
levels are associated with an even lower risk of diabetes.
Observational studies using Mendelian randomization 
approaches, which offer the potential advantage that the 
reported genetic associations with phenotypes may over-
come the challenges of confounding and reverse causation, 
have shown inconsistent associations between certain al-
leles relevant to vitamin D physiology and incident type 2 
diabetes (30–34). In a Danish study of 96 423 adults, gen-
etic variants associated with low blood 25(OH)D levels pre-
dicted incident type 2 diabetes (33). However, other studies 
in different cohorts have reported no associations between 
genetic variants that specifically affect blood 25(OH)D level 
and incident diabetes (30–32, 34). Mendelian randomiza-
tion studies center upon certain assumptions that may not 
apply to vitamin D. Specifically, the tested alleles accounted 
for less than 5% of the variance in blood 25(OH)D level. 
Furthermore, Mendelian randomization studies did not 
predict the amounts of bioavailable or biologically active 
vitamin D and cannot distinguish between endogenous 
versus exogenous sources of vitamin D or long-term versus 
short-term exposure to vitamin D.  In the study by Afzal 
et  al, variation in the DHCR7 gene, which is associated 
with lower vitamin D biosynthesis, predicted risk of type 2 
diabetes, suggesting that sustained, long-term exposure to 
vitamin D may be important for the prevention of diabetes 
(33). Mendelian randomization studies may also be con-
founded by pleiotropic effects of genetic variants and are 
further limited by the assumption of a linear association be-
tween genetic variants, blood 25(OH)D level, and diabetes 
risk, which may not hold. Despite their theoretical appeal, 
Mendelian randomization studies can neither support nor 
exclude a causal relationship between vitamin D and type 
2 diabetes.
Most longitudinal observational studies have included 
people with an average risk of type 2 diabetes at baseline. 
The inverse association between blood 25(OH)D level and 
incident diabetes may be more pronounced among persons 
who are already at a high risk for type 2 diabetes (9).
Consideration of alternative explanations
Despite very promising and consistent data from observa-
tional studies, relying on observational data alone to es-
tablish causality is not sufficient, as evidenced by carefully 
examining the multiple determinants of the one’s vitamin D 
status, as reflected in one’s blood 25(OH)D level.
Vitamin D is obtained from oral sources or cutaneous 
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routes (Figure 1). The amount of vitamin D that reaches 
the circulation from oral sources is influenced by food se-
lection, food fortification, supplement use, and absorption 
efficiency. For example, absorption is increased when sup-
plemental vitamin D is co-ingested with a meal containing 
fat and it is decreased by medical conditions that produce 
intestinal malabsorption (35). Cutaneous biosynthesis de-
clines with age and is reduced by higher levels of melanin in 
the skin (36). Season, latitude, altitude, time of day, ozone 
layer, and pollution also influence the degree of effective cu-
taneous biosynthesis. Individuals with a higher body weight 
have lower circulating vitamin D levels, probably reflecting 
the larger pool size over which vitamin D metabolites are 
distributed (37). Assuming that the supply of the precursor 
(vitamin D) is not rate-limiting, the blood 25(OH)D level 
reflects the balance between liver production, the genetic-
ally determined amount of vitamin D binding protein, and 
the metabolism of 25(OH)D to 1,24-dihydroxyvitamin D 
(1,24[OH]2D) or to 24,25-dihydroxyvitamin D (inactive 
metabolite).
Several factors that influence the blood 25(OH)D level 
also independently influence the risk of developing type 2 
diabetes (Fig. 1). Chief among these are body weight and 
fatness, most frequently assessed by the body mass index 
(BMI). Specifically, a higher BMI is associated with both 
an increased risk of diabetes and a lower blood 25(OH)D 
level; hence, it is a potentially large source of confounding. 
Related to this, persons who are more physically active 
also tend to have a lower BMI and a lower risk of dia-
betes. When physical activity takes place out-of-doors, the 
increased cutaneous biosynthesis of vitamin D increases the 
circulating 25(OH)D level. Collectively, these factors are 
potential confounders in observational studies reporting on 
the association between blood 25(OH)D levels and the risk 
of developing type 2 diabetes.
Many other conditions, although not directly related 
to diabetes risk, affect 25(OH)D levels and may alter the 
reported association of 25(OH)D level with diabetes risk. 
For example, the association of 25(OH)D level with dia-
betes risk may not be linear, thus observational studies in 
populations that do not have a broad distribution of blood 
25(OH)D levels may provide a misleading or incomplete 
picture of the true relationship between vitamin D status 
and diabetes risk.
Experimental evidence (clinical trials)
There are 10 trials published between 2008 and 2019 that 
have reported on the effect of vitamin D supplementa-
tion on incident diabetes (12–19, 38, 39) (Table 2). Two 
large trials were designed and conducted for nondiabetes 
outcomes and reported data on incident diabetes in post 
hoc analyses (38, 39). These 2 trials enrolled patients who 
were at average risk for diabetes (ie, not prediabetes), the 
intervention included low-dose vitamin D (400 and 800 
IU daily) co-administered with calcium, and diabetes was 
ascertained by participants’ self-report based on a diag-
nosis made outside of the study in routine clinical prac-
tice. Eight trials that have reported data on the effect of 
vitamin D supplementation and incident diabetes included 
Figure 1. Factors (determinants) that contribute to low blood 25-hydroxyvitamin D (25[OH]D) concentration. Factors shown in bold are also associ-
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persons with prediabetes (12–19). Five of these trials have 
major limitations, including a small sample size (109–205 
participants) (12–15, 18), not being designed for incident 
diabetes as the primary outcome (12, 14, 15, 18), a short 
duration (≤1 year) (12, 14, 15, 18), and open-label study 
design (13, 15). Therefore, results from these 5 trials  (12–
15, 18) and the 2 large trials where incident diabetes was 
a post-hoc outcome (38, 39) are not informative in our 
understanding of the role of vitamin D supplementation 
for diabetes prevention in the clinical setting.
Three double-blind, placebo-controlled, randomized 
trials have been designed and conducted specifically to test 
the hypothesis that vitamin D supplementation lowers the 
risk of diabetes among persons with prediabetes (16, 17, 
19, 40, 41). Below, we describe these most relevant trials 
in detail.
The Tromsø  study. The Tromsø study was a single-site 
trial that took place from March 2008 through March 
2015 in Norway (16). The study randomly assigned 511 
adults (mean age 62 years, mean BMI 30 kg/m2) who met 
at least 1 of 2 glycemic criteria for prediabetes (FG 108–
125  mg/dL; glucose 2 hours after a 75-gram oral glucose 
load [2hG] 140–199 mg/dL) to treatment with 20 000 IU 
of vitamin D3 weekly (about 2857 IU per day) or placebo. 
The primary outcome was time-to-incident diabetes 
based on annual glycemic testing through FG, HbA1c, 
and 2hG. Mean baseline serum 25(OH)D level was 24 ng/mL 
(60.0 nmol/L) and 68% of participants had a level ≥20 ng/
mL (49.1 nmol/L) (Table 3). During follow-up, mean serum 
25(OH)D level in the vitamin D group rose to 44.1  ng/
mL compared to 25.6  ng/mL in the placebo group. After 
a median follow-up of 2.5  years, 215 diabetes events had 
occurred: 103 in the vitamin D group and 112 in the placebo 
group (11.8 events vs 13.1 events per 100 person-years, 
respectively). In the intention-to-treat (ITT) analysis, the 
risk of diabetes was not significantly lower in the vitamin 
D group (hazard ratio 0.90; 95% confidence interval [CI]: 
0.69–1.18) (16).
Diabetes Prevention with Active Vitamin D  study. The 
Diabetes Prevention with Active Vitamin D (DPVD) 
study was a 3-site trial that took place from June 2013 
through August 2018 in Japan (17, 41). The study 
randomly assigned 1256 adults (mean age 61 years, mean 
BMI 24 kg/m2) who met the impaired glucose tolerance 
criterion for prediabetes (2hG 140–199 mg/dL) and had 
no diabetes (FG  <  126  mg/dL and HbA1c  <  6.5%) to 
treatment with 0.75  mg of eldecalcitol (an analog of 
the active form of vitamin D3) daily or placebo. The 
primary outcome was time-to-incident diabetes based 
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2hG, and quarterly with FG and HbA1c. Information on 
mean baseline blood 25(OH)D level and proportion of 
participants with a level ≥20 ng/mL is not yet available. 
Based on results published in abstract form, after a 
median follow-up of 2.8 years, 121 diabetes events had 
occurred: 57 in the vitamin D group and 64 in the placebo 
group. In the ITT analysis, the risk of diabetes was not 
significantly lower in the vitamin D group (hazard ratio 
0.87; 95% CI: 0.68–1.09) (17).
The Vitamin D and Type 2 Diabetes trial. The Vitamin D 
and Type 2 Diabetes (D2d) study was a 22-site trial that 
took place from October 2013 through December 2018 in 
the United States (19, 40). The study randomly assigned 
Table 3. Main Characteristics of the Key Randomized, Placebo-controlled Clinical Trials on Vitamin D Supplementation and 
Prevention of Diabetes Among Adults at Risk for Type 2 Diabetes (Prediabetes)
Study name, first author, year of 
publication (reference)
The Tromsø study, Jorde 
et al, 2016 (16)
The DPVD study, 
Kawahara et al, 2018 
(17)
The D2d study, Pittas et al, 2019 
(19)
Country (number of sites) Norway (1 site) Japan (3 sites) United States (22 sites)
Year of trial completion 2015 2018 2018
Number of randomized participants 511 1256 2423
Prediabetes glycemic criteria for 
eligibility
IFG (FG 108–125 mg/
dL) and/or IGT (2hG 
140–199 mg/dL) and no 
criterion in the diabetes 
category
IGT (2hG 140–199 mg/
dL) and no criterion in 
the diabetes category
Two or 3 glycemic criteria (IFG [FG 100–
125 mg/dL], IGT [2hG 140–199 mg/
dL], HbA1c 5.7–6.4%) and no 
criterion in the diabetes category
Serum 25(OH)D level, ng/mL 24 Not available 28
Participants with blood 25(OH)D 
level above 20 ng/mL, %
62 Not available 78
Interventiona Cholecalciferol (vitamin 
D3), 20 000 IU weekly 
(~2857 IU daily) vs 
placebo
Eldecalcitol, 0.75 
micrograms daily vs 
placebo 
Cholecalciferol (vitamin D3), 4000 IU 
daily vs placebo
Vitamin D amount from supplements 
allowed outside of the study
≤400 IU/day No amount was allowed ≤1000 IU/day





dL, HbA1c ≥ 6.5% (a 





dL, or casual 
glucose ≥ 200 mg/dL
Two or 3 glycemic-positive criteria: 
FG ≥ 126 mg/dL, 2hG ≥ 200 mg/dL, 
HbA1c ≥ 6.5%, or 1 criteria positive 
with confirmation
Expected incidence of diabetes 
in the placebo group, per 100 
person-years
10.0 8.4 10.5
Expected relative risk reduction, 
vitamin D vs placebo, %
30 36 25
Median (range) duration of follow-up, 
yearsc
4 (0–5) 2.8 (not available) 2.5 (0–4.5)
Hazard ratio (95% CI) for incident 
diabetes, vitamin D vs placebo
0.90 (0.69–1.18) 0.87 (0.68–1.09) 0.88 (0.75–1.04)
Hazard ratio (95% CI) for incident 
diabetes among participants 
with starting serum 25(OH)D 
level < 12 ng/mL, vitamin D vs 
placebo
Data not available Data not available 0.38 (0.18–0.80)
Abbreviations: 2hG, 2-hour glucose after a 75-gram oral glucose load; 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; FG, fasting glucose; HbA1c, he-
moglobin A1c; IFG, impaired fasting glucose; IGT, impaired glucose tolerance. 
a Randomization ratio was 1:1 in all trials.
b In the Tromsø study (N = 2 participants) and D2d study (N = 38 participants), diabetes was diagnosed outside of the study and confirmed by adjudication. In the 
DPVD study, no participant was diagnosed with diabetes outside of the study.
c The Tromsø study followed participants for up to 5 years. The D2d study was designed as an event-driven trial and follow-up varied among participants. The 
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2423 adults (mean age 60 years, mean BMI 32 kg/m2) who 
met at least 2 of 3 glycemic criteria for prediabetes (FG 
100–125 mg/dL; 2hG 140–199 mg/dL; HbA1c 5.7–6.4%) 
to treatment with 4000 IU of vitamin D3 daily or placebo. 
The primary outcome was time-to-incident diabetes based 
on annual glycemic testing through FG, HbA1c and 2hG, 
and semiannually with FG and HbA1c. The trial design 
was event-driven, with a target number of diabetes events 
of 508. Mean baseline serum 25(OH)D level was 28 ng/mL 
(69 nmol/L) and 78% of participants had a level ≥20 ng/
mL (49 nmol/L) (Table 3). During follow-up, mean serum 
25(OH)D level in the vitamin D group rose to 54 ng/mL 
compared with 29  ng/mL in the placebo group. After a 
median follow-up of 2.5  years, 616 diabetes events had 
occurred: 293 in the vitamin D group and 323 in the 
placebo group (9.4 events vs 10.7 events per 100 person-
years, respectively). In the ITT analysis, the risk of diabetes 
was not significantly lower in the vitamin D group (hazard 
ratio 0.88; 95% CI: 0.75–1.04) (19).
In each of these 3 studies, protocol-specified adverse 
events of interest (hypercalcemia, hypercalciuria, and 
nephrolithiasis) were rare, and there were no significant 
differences between vitamin D and placebo.
Challenges of vitamin D clinical trials
A clinical trial is often labeled as “positive” or “negative” 
based on whether the P-value for the statistical test for the 
primary outcome falls below or above (respectively) the 
traditional threshold of 0.05. This “dichotomania,” which 
is based on an arbitrary threshold, provides clarity for 
regulatory agencies when deciding whether to approve a 
pharmaceutical agent for clinical use; however, it is overly 
simplistic when trying to determine whether an interven-
tion has a real and clinically meaningful effect (42). When 
the primary outcome in a clinical trial “fails,” there are sev-
eral considerations that may clarify whether the interven-
tion may still have clinical value (43). We modified a set 
of questions, described in the article by Pocock and Stone 
(43), for relevance to trials on vitamin D supplementation 
for the prevention of type 2 diabetes (Table 4). Below we 
address these questions in relation to the 3 major trials 
described above.
Is there some indication of potential benefit? When the 
primary outcome result is entirely neutral, concluding 
that the intervention has no effect is straightforward. 
Individually, each trial reported a result for the primary 
outcome of incident diabetes that did not reach the 
traditional 5% level of statistical significance; yet there 
is an indication of benefit from vitamin D, as all trials 
reported hazard ratios favoring the vitamin D treatment 
over placebo that were remarkably similar among the trials 
(0.87, 0.88, and 0.90).
Were the trials underpowered? Each trial was powered to 
detect a 25% to 36% relative risk reduction in incident 
diabetes with vitamin D supplementation compared 
with placebo (16, 40, 41). Based on the results, vitamin 
D supplementation appears to decrease diabetes risk 
among people with prediabetes not selected for vitamin D 
insufficiency by a smaller effect (~10–13%), but each trial 
was individually underpowered to test modest treatment 
effects. Of interest, in the Tromsø study and D2d study, 
the hypothesized relative risk reductions (30% and 25%, 
respectively) were within the reported 95% CI (0.69–1.18 
and 0.75–1.04, respectively) (16, 19). Furthermore, as 
the size of the trial population increased, the reported 
95% CI narrowed (Table 3). Therefore, it would be more 
appropriate to describe the findings of each individual trial 
as inconclusive rather than “negative.”
Were the trial populations appropriate? Selection of an 
appropriate trial population based on evidence from 
observational cohorts and mechanistic studies and good 
clinical judgment is essential. It has been suggested that 
vitamin D supplementation may be of benefit if started 
early in the natural history of type 2 diabetes. Despite its 
theoretical appeal, early supplementation presents multiple 
challenges. For example, diabetes progression is expected 
to be slow and vitamin D (or any intervention) is unlikely 
to have a detectable and clinically meaningful effect on 
diabetes risk if applied in people who are at an average 
risk for diabetes (38, 39). Furthermore, because the rate of 
progression from normal glucose tolerance to diabetes is 
highly dependent upon specific population characteristics, 
calculating study size and length of follow-up needed for 
such a clinical trial is complicated. For these reasons, all 
3 trials appropriately enrolled people with prediabetes 
Table 4. Questions to Address When the Primary Outcome 
“Fails” in Trials of Vitamin D Supplementation for Diabetes 
Prevention
1. Is there some indication of potential benefit?
2. Was the trial underpowered?
3. Was the trial population appropriate?
4. Was the treatment regimen appropriate?
5. Was the primary outcome appropriate or accurately defined?
6. Was the intervention/follow-up duration appropriate?
7.  Were there deficiencies in trial conduct (eg, under-recruitment, 
poor retention, poor adherence, use of rescue medication)?
8. Do subgroup findings elicit positive signals?
9. Can alternative analyses help?
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who are most likely to benefit from interventions to lower 
risk of progression to diabetes. Notably, all trials defined 
prediabetes by specific glycemic criteria (FG, HbA1c, 2hG), 
expanding their translational potential.
For ethical and practical reasons, the trials did not in-
clude blood 25(OH)D level as an eligibility criterion and 
did not measure blood 25(OH)D levels in real time. Because 
of frequent testing for vitamin D status in routine clinical 
settings and the widespread use of over-the-counter vitamin 
D supplements (44), trial participants were mostly vitamin 
D replete by current vitamin D recommendations (blood 
25[OH]D level ≥ 20 ng/mL [50 nmol/L]) when the trials 
started and participants in the placebo group remained 
vitamin D replete during the follow-up (16, 19).
Were the treatment regimens appropriate? Determining 
the appropriate formulation and dose of vitamin D and 
timing of administration (eg, daily, weekly, monthly, yearly) 
in vitamin D trials can be challenging. The Tromsø study 
and D2d study administered vitamin D3 (cholecalciferol), 
the most commonly consumed vitamin D formulation, 
and thereby increased the studies’ translational potential. 
The DPVD study administered eldecalcitol, an analog of 
the active metabolite of vitamin D3 that does not require 
activation in the liver and kidney. Although infrequent 
dosing (eg, monthly, yearly) of vitamin D is convenient, 
it produces fluctuating blood 25(OH)D levels and is 
considered nonphysiologic (45, 46); therefore, daily or 
weekly dosing is preferred. The doses used (20  000 IU 
weekly [~2857 IU per day] in the Tromsø study, 0.75 mcg 
of eldecalcitol daily in the DPVD study, and 4000 IU daily 
in the D2d study) provide an appropriate balance of safety 
and efficacy in terms of obtaining an adequate difference 
in vitamin D status between the active and placebo groups.
All 3 trials appropriately compared vitamin D alone to 
placebo in a double-blind design. For practical and ethical 
reasons, all trials allowed participants to take outside-of-
study vitamin D from all supplemental sources up to a cer-
tain amount and did not limit vitamin D intake from food 
sources. Many vitamin D trials have combined vitamin D 
with calcium or administered vitamin D in foods (eg, yogurt) 
and have used comparators other than placebo (13, 15, 38, 
39). Such study designs are not informative regarding the 
role of vitamin D alone for diabetes prevention because they 
cannot isolate the effect of vitamin D from other compo-
nents of the intervention.
Was the primary outcome appropriate or accurately 
defined? In all 3 trials, ascertainment for diabetes took 
place at regular intervals (every 3 or 6  months) by 
blood glucose testing using a single (central) laboratory 
and diabetes was appropriately defined based on strict, 
trial-specific glycemic criteria. Such an approach is robust 
and unbiased compared with other trials that relied on a 
self-reported diagnosis of diabetes outside of the study 
(38, 39), which is influenced by many uncontrolled factors 
that contribute random noise, potentially shifting the risk 
difference between vitamin D and placebo towards the 
null.
Was the duration of intervention and follow-up too short? 
Trial duration is an important consideration and one that 
requires careful weighing of competing factors. An adequate 
intervention period is essential given the long latency period 
for progression from prediabetes to diabetes and variable 
rate of progression (5–10% per year). Long-term trials 
encounter obligatory losses of participants due to a variety 
of unrelated intercurrent events. Secular changes in the 
perception of the value of the intervention may occur and 
lead to altered outside-of-study use of vitamin D, often at 
high doses. The adherence to study procedures may decline 
as participants experience study fatigue, leading to losing 
interest in continuing their participation. These occurrences 
reduce study power and increase the opportunity for 
postrandomization confounding.
The Tromsø study (mean 4  years, maximum 5 years), 
the DPVD study in Japan (mean 2.6  years, maximum 
3  years), and the D2d study (mean 2.5  years, maximum 
4.5  years) appear to have achieved a reasonable balance 
with regard to duration (16, 17, 19). In the D2d study, the 
Kaplan-Meir curves for incident diabetes in the vitamin D 
and placebo groups converged towards the end of the trial, 
indicating a low likelihood of a latent benefit from vitamin 
D supplementation.
Were there deficiencies in trial conduct? Based on full-text 
publications describing study results, the Tromsø study 
and D2d study were well conducted (16, 19). The design 
of the DPVD study is robust (41); however, results have 
been published in abstract form only (17), therefore the 
DPVD study conduct cannot be evaluated. All 3 trials met 
their recruitment goals. Retention in the Tromsø and D2d 
studies was excellent, with more than 99% of participants 
contributing follow-up data. Adherence to the trial regimen 
in the Tromsø and D2d studies was also excellent, with 
more than 85% of prescribed pills taken and fewer than 
4% of trial participants taking out-of-study vitamin D 
supplements above the trial limit. In the D2d study, 1% of 
participants took diabetes or weight-loss medication before 
the diagnosis of diabetes was established. In the Tromsø 
and DPVD studies, none did.
Do subgroup findings elicit positive signals? Response to 
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Thus, people with higher baseline levels of blood 25(OH)
D would benefit less from vitamin D supplementation than 
people with lower baseline levels (48). The high proportion 
of participants with adequate blood 25(OH)D levels at 
baseline may have prevented the detection of statistically 
significant differences between the vitamin D and placebo 
groups in the full trial cohorts. In all 3 trials, among 
participants with baseline blood 25(OH)D levels < 20 ng/
mL, the risk of diabetes with vitamin D supplementation 
was reported to be lower compared with participants with 
levels ≥20 ng/mL, but the differences were not statistically 
significant. In the D2d study, the risk of diabetes was 
significantly lower in a small subgroup of participants 
with a baseline 25(OH)D level < 12 ng/mL (hazard ratio 
0.38; 95% CI: 0.18–0.80; p for interaction = 0.023) (19). 
Results from subgroup analyses need to be interpreted 
cautiously partly because of the potential of a type I error 
(false positive) due to multiple analyses (49). However, 
given strong preexisting biologic plausibility, vitamin D 
supplementation may be more important in reducing 
diabetes risk among persons with prediabetes and low 
vitamin D status.
Can alternative analyses  help? The ITT analyses are 
generally favored because of simplicity and because they 
alleviate concerns about confounding. However, although 
large scale trials are free of confounding when they start, 
biases may emerge during follow-up due to incomplete 
adherence to the trial intervention or use of rescue 
medications leading to postrandomization confounding, 
which may influence the estimate of treatment efficacy 
and study power (50, 51). The ITT analyses are agnostic 
to postrandomization confounding, including treatment 
discontinuation and concomitant therapies (eg, rescue 
medications such as high-dose vitamin D or metformin 
in trials for the prevention of diabetes with vitamin D) 
not allowed by the study protocol; hence, ITT analyses 
estimate the effect of treatment assignment, not the effect 
of treatment itself (51).
Differential adherence (for any reason) to the assigned 
intervention and concomitant exogenous use of vitamin 
D are common challenges in vitamin D trials given the 
widespread laboratory testing for blood 25(OH)D in the 
routine clinical setting and the availability of over-the-
counter vitamin D supplements at high doses. These fac-
tors have the significant potential to influence the estimate 
of efficacy of vitamin D intervention for the prevention of 
diabetes in clinical trials. For example, in the D2d study, 
although overall adherence to the protocol was high and 
overall use of rescue medications was low, a different pat-
tern among nonadherent participants emerged between the 
2 groups. Specifically, during follow-up, more participants 
in the placebo group started diabetes or weight-loss medi-
cations, which would make the detection of diabetes less 
likely. Furthermore, more participants in the placebo group 
took personal vitamin D supplements above the trial limit, 
likely due to testing outside of the study. These differences 
may have shifted the relative risk reduction towards null 
in the ITT analysis. In a prespecified, per-protocol analysis 
that censored follow-up when a D2d participant started a 
diabetes or weight-loss medication, stopped study pills, or 
took out-of-study vitamin D from supplements that were 
above the study limit, the risk of diabetes was significantly 
lower in the vitamin D group (hazard ratio 0.84; 95% CI: 
0.71–1.00) (19).
Were there any safety signals with the intervention? None 
of these trials reported a higher risk of adverse events with 
vitamin D supplementation versus placebo. In the Tromsø 
study, there were no significant differences in the protocol-
specified adverse events of interest (hypercalcemia and 
kidney stones) or serious adverse events. The D2d study 
used cholecalciferol at 4000 IU/day, which is the tolerable 
upper intake level set by the National Academy of Medicine 
to avert potential toxicity. There were no significant group 
differences in the protocol-specified adverse events of 
interest (hypercalcemia, hypercalciuria, low glomerular 
filtration rate, and kidney stones) or serious adverse events. 
In abstract form, the DPVD study reported no serious 
adverse events with eldecalcitol, but the full determination 
of safety will await publication of the complete report.
Coherence/Consistency Among Studies
Longitudinal observational studies show highly consistent 
associations between higher blood 25(OH)D levels and 
a lower risk of incident diabetes in diverse populations, 
including populations with prediabetes. Two meta-analyses 
from 2 different groups that combined aggregate data from 
trials on vitamin D for diabetes prevention were recently 
published. Zhang et  al synthesized results from 8 trials 
(total of 4896 participants) in persons with prediabetes and 
reported a significant benefit of vitamin D supplementation 
for incident diabetes (risk ratio 0.89; 95% CI: 0.80–0.99) 
(52). The authors also reported that participants assigned 
to vitamin D supplementation were more likely to revert to 
euglycemia than the nonvitamin D group (risk ratio 1.48; 
95%: CI 1.14–1.92). Barbarawi et  al synthesized results 
from 9 trials (total of 43 559 participants). Two trials not 
designed for diabetes prevention (total of 39 243 partici-
pants) were in persons of average diabetes risk randomized 
to low-dose vitamin D (<1000 IU per day); 7 trials (total of 
4316 participants) designed for diabetes prevention were in 
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D (≥1000 IU per day). The authors reported a significant 
benefit of vitamin D supplementation for incident diabetes 
only after combining data from the diabetes prevention 
trials among persons with prediabetes who also received 
high-dose vitamin D (risk ratio 0.88; 95% CI: 0.79–0.99; 
p = 0.043) (53).
Evidence Synthesis and Next Steps
Given the highly consistent results from the existing lon-
gitudinal observational studies, it is unlikely that new 
observational studies would modify the conclusion that 
vitamin D status is inversely associated with diabetes risk. 
A  search of clinicaltrials.gov did not identify ongoing or 
planned randomized controlled trials specifically designed 
and being conducted to test the effect of vitamin D sup-
plementation for the prevention of type 2 diabetes. Many 
large trials testing the effect of vitamin D supplementation 
on nondiabetes outcomes in populations at average risk for 
diabetes have been recently published or will be completed 
soon (54–58). We expect many of these trials to present sec-
ondary results on incident diabetes; however, these reports 
will require careful interpretation due to several limitations 
(eg, enrolled population at low/average risk, inadequately 
defined diabetes outcome). Therefore, the conclusions we 
draw on the role of vitamin D for the prevention of type 2 
diabetes will depend on data we already have.
We also expect many of the completed trials to pub-
lish secondary results on the effect of vitamin D supple-
mentation on micro- and macrovascular complications 
of diabetes. However, these trials are not powered for 
detecting an effect because the risk of developing micro- 
and macrovascular complications in these trial populations 
is very low.
Application of the Bradford Hill criteria to evaluate the 
totality of available evidence from longitudinal observa-
tional studies and clinical trials indicates a causal relation 
between vitamin D status and risk of type 2 diabetes. When 
combining data from the 3 large trials that were specifically 
designed and conducted to test vitamin D for diabetes pre-
vention, Zhang et al reported a 12% reduction in diabetes 
risk with vitamin D supplementation (hazard ratio 0.88, 
95% CI: 0.78–0.99) among participants with prediabetes 
not selected for vitamin D deficiency (52). Vitamin D 
supplementation may be more beneficial in adults with 
prediabetes and low vitamin D status, as suggested by the 
subgroup analysis in the D2d study that showed a 62% 
reduction (range 20–82%) in diabetes risk with vitamin D 
supplementation compared with placebo among partici-
pants with baseline serum 25(OH)D level < 12 ng/mL.
When evaluating the potential benefit of vitamin D 
supplementation, we should also not discount the benefit 
of the reversal of prediabetes to euglycemia. If vitamin D 
supplementation promotes regression to euglycemia, then 
more people will spend more time in the low-risk state 
away from prediabetes/diabetes. Therefore, the higher 
likelihood of reversal to euglycemia with vitamin D sup-
plementation (~48% more likely, as stated by Zhang 
et al) may, by delaying time-to-onset of diabetes, repre-
sent an additional benefit to the 12% lower risk to pro-
gression to diabetes reported by the 2 meta-analyses of 
clinical trials (52, 53).
Although the summary results reported by Zhang et al 
and Barbarawi et  al are concordant, meta-analyses that 
combine aggregate data from trials that vary in study de-
sign and quality should be interpreted cautiously (59). 
Individual participant data meta-analyses that combine 
data from high-quality clinical trials specifically designed 
and conducted to test the hypothesis are necessary to (1) es-
timate with precision the benefit of vitamin D supplementa-
tion on diabetes progression and regression to euglycemia, 
(2) assess heterogeneity of the treatment effect in order to 
define prediabetes subpopulations most likely to benefit 
most likely to benefit from vitamin D supplementation, and 
(3) evaluate safety using time-to-event analyses.
Conclusion
Answers to clinically important questions are rarely dichot-
omous (“positive” or “negative”), and a recommendation 
of whether “to D or not to D” should be made based on 
the best available data from both observational studies and 
clinical trials. Results from trials are congruent with a large 
body of evidence from observational studies indicating that 
vitamin D has a role in modulating diabetes risk. We are 
awaiting the full publication of the DPVD study and results 
from individual participant data meta-analyses. Even if the 
risk reduction with vitamin D supplementation may appear 
relatively small, when applied in the expanding prediabetes 
population, it can have important public health implications.
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